|
0
|
|
Alzheimer's disease.
(linkinghub.elsevier.com)
|
Serrano-Pozo A
…
Sperling RA
The Lancet
2026-05-30
|
#imaging
#neurodegeneration
#genetics
#biomarker
|
|
0
|
|
Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study.
(linkinghub.elsevier.com)
|
Jiang X
…
Yaffe K
The Lancet
2026-05-30
|
#cognition
#neurodegeneration
#biomarker
#neuropathology
|
|
0
|
|
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
(linkinghub.elsevier.com)
|
Nikolcheva T
…
Bonni A
The Lancet
2026-05-30
|
#clinical trial
#immunotherapy
#neurodegeneration
#neuroprotection
|
|
0
|
|
Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.
(linkinghub.elsevier.com)
|
Povala G
…
Pascoal TA
The Lancet
2026-05-30
|
#neuroimaging
#neurodegeneration
#biomarker
#tau pathology
#pet imaging
|
|
0
|
|
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
(linkinghub.elsevier.com)
|
Cummings JL
…
Feldman HH
The Lancet
2026-05-30
|
#clinical trial
#neurodegeneration
#neuroprotection
#pharmacotherapy
#dementia
|